Overview

Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Status:
Completed
Trial end date:
2017-04-24
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the long-term safety of IDP-118 lotion.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.
Collaborator:
Dow Pharmaceutical Sciences
Treatments:
Halobetasol
Tazarotene